Programa de Pós-Graduação em Oncologia e Ciências Médicas - PPGOCM/NPO
URI Permanente desta comunidadehttps://repositorio.ufpa.br/handle/2011/4631
O Programa de Pós-Graduação em Oncologia e Ciências Médicas (PPGOCM) integra o Núcleo de Pesquisas em Oncologia (NPO) da Universidade Federal do Pará (UFPA). Trata-se do único centro de referência em pesquisa e formação de recursos humanos stricto sensu na área de oncologia na região Norte do Brasil. Os outros centros se concentram nas cidades do Rio de Janeiro e São Paulo.
Navegar
Navegando Programa de Pós-Graduação em Oncologia e Ciências Médicas - PPGOCM/NPO por CNPq "CNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA"
Agora exibindo 1 - 5 de 5
- Resultados por página
- Opções de Ordenação
Item Acesso aberto (Open Access) Análise da expressão gênica diferencial entre o adenocarcinoma da junção esôfago-gástrica e o adenocarcinoma gástrico(Universidade Federal do Pará, 2016-03-03) MASCARENHAS JUNIOR, Rui Wanderley; ASSUMPÇÃO, Paulo Pimentel de; http://lattes.cnpq.br/7323606327039876Gastric cancer is the fifth most common malignancy worldwide and the third in mortality. In 2010, UICC released the latest edition of the TNM staging manual in the adenocarcinoma esophageal-gastric junction (JEG) with epicenter at 5 cm from the JEG and extending into the esophagus is classified and staged together with the esophageal tumors, while those that do not extend into the esophagus remain classified and staged as gastric adenocarcinoma. This change was due to differences between adenocarcinomas of the JEG and stomach, risk factors, treatment and prognosis. With the development of molecular biology, several areas - such as transcriptomics, studying gene expression on a genomic scale - started to be used to explore differences in expression in various tumor types. In this sense, the Atlas Genomic Cancer (TCGA) is a database that aims to generate complete maps of the genomic key changes of the major types of cancer, in order to accelerate the understanding of the molecular basis of cancer through the application of technology genome analysis, which makes it a powerful tool in this area. Considering these aspects, the aim of this study is to comparatively analyze the transcriptome of adenocarcinomas of the JEG and gastric using TCGA data as a tool for validation. To this end, the gastrectomy at the University Hospital João de Barros Barreto eight patients samples were obtained submitted, four adenocarcinomas of the JEG and four gastric adenocarcinomas. Samples were analyzed using the technique of expression microarray chips with Human Gene 1.0 ST Array (Affymetrix®) which allow the analysis of 36,079 transcripts. The transcriptome analysis revealed 36 genes differentially expressed (fold-change greater than or equal to 5), 11 and 25 hipoexpressos hiperexpressos genes in JEG adenocarcinoma in relation to gastric adenocarcinomas. In the analysis of TCGA were identified 509 differentially expressed genes (p <0.05), and the ASPN genes, LiPF HNRNPM and validated for this database. Thus, it is concluded that the differential gene analysis shows significant changes between gastric adenocarccinoma and JEG and its molecular differences may reflect the clinical features, stressing that these tumors should be classified and staged differently.Item Acesso aberto (Open Access) Associação de polimorfismos de biomarcadores do envelhecimento (TP53, MDM2, UCP2, HLA-G, IL-1a, IL-4 e NFkB1) com a capacidade funcional de idosos(Universidade Federal do Pará, 2016-05-30) PEREIRA, Esdras Edgar Batista; SANTOS, Sidney Emanuel Batista dos; http://lattes.cnpq.br/9809924843125163; SANTOS, Ney Pereira Carneiro dos; http://lattes.cnpq.br/1290427033107137INTRODUCTION: The functional capacity and overall functionality of the elderly is defined as the capacity to manage their lives or take care of yourself, which is influenced by the degree of autonomy and independence of the individual. In search of understanding of the mechanisms involved in healthy aging and maintenance of functional independence, several studies try to identify candidate genes that may establish the association of genotype with phenotype studied physical fitness and the decline and loss of independence in adulthood. OBJECTIVE: The objective of this study was to investigate the possible association between the variability of polymorphisms on biomarkers of aging (TP53, MDM2, UCP2, HLA-G, IL-1a, IL-4 and NFkB1) with the functional capacity of the elderly. MATERIAL AND METHODS: This is a comparative analytical cross-sectional study, developed from the clinical and functional evaluation and analysis of polymorphisms on biomarkers of aging. The clinical and functional analysis included an assessment of functional capabilities: basic activity of daily living (ABVD), instrumental activities of daily living (AIVD), advanced activities of daily living (AAVD) and functional status (PS-ECOG) functional systems: cognition (MEEM), humor (GDS-15), mobility (TUG) and risk of falls (TT), Nutritional Status (MAN) and Sarcopenia risk (PP). Eight polymorphisms were included (two TP53, MDM2, UCP2, HLA-G, IL-1a, IL-4 and NFkB1) were genotyped by a multiplex PCR reaction followed by capillary electrophoresis. Analysis of PCR amplicons was performed by electrophoresis using the ABI Prism sequencer 3130 and GeneMapper ID v.3.2 software. RESULTS: A total of 228 elderly, mostly women (62%), with about 70 years old on average, with an average comorbidity index of 4.48 (± 2.44) points, sedentary (53%), with a history smoking (58%) and possessing a predominantly European ancestry. It was found that polymorphisms of the TP53 gene, UCP2, HLA-G, IL-1a, IL-4 and NFkB1 significant differences in functional variables between genotypes. The variables that most differed between genotypes were functional status (PS-ECOG), mobility (TUG), risk of falls (TT) and the risk of sarcopenia (PP). This suggested a possible association of these polymorphisms with risk factors or protection, which in most cases were not significant. The NFkB1 gene polymorphism (rs28362491) was the only biomarkers that demonstrated significant association results. The II genotype of this polymorphism was associated with risk of sarcopenia (PP). The elderly who had this genotype showed a three-fold greater susceptibility to muscle loss related to aging, when compared to other genotypes of the same gene. CONCLUSION: Therefore, considering the results of this study, it is believed that the use of biomarkers of aging, as a population screening test may favor the identification of elderly patients with increased susceptibility to the development of organic modifications and functional disabilities. The identification of this risk allows the targeting of strategies for prevention, control and treatment of disabilities linked to physiological or pathological aging.Item Acesso aberto (Open Access) Influência da suplementação de vitamina D na variabilidade glicêmica em pacientes com diabetes Mellitus tipo 1(Universidade Federal do Pará, 2016-01-27) FELÍCIO, Karem Mileo; YAMADA, Elizabeth Sumi; http://lattes.cnpq.br/7240314827308306; FELÍCIO, João Soares; http://lattes.cnpq.br/8482132737976863Recent studies suggest that glycemic variability (GV) could influence the risk of complications in diabetes, independently from glycemic control (GC). GV is the evaluation of the daily fluctuations of glycemia through specific calculations. The few studies that have assessed the effects of supplementation with vitamin D (VD) in patients with diabetes type 1(DM1) on GC are controversial and there is no data about a possible action of VD on GV in these patients. Our study aims to evaluate the effects of VD supplementation on GV in patients with DM1. We executed a prospective, controlled study with 22 patients with DM1. Doses of either 4.000 or 10.000 IU/day of cholecalciferol were administered for 12 weeks according to the patient’s previous vitamin D serum levels. All patients were submitted to continuous glucose monitoring system (CGMS) with the analysis of 41.000 glycemias, dosage of vitamin D and HbA1c before and after the treatment. When the pre and post treatment variables were compared, no differences were observed, except for the expected improvement of the levels and status of VD (26,1 ± 9,0 vs 44,4 ± 24,7 ng/mL ; p<0,01 e 1,00 ± 0,76 vs 0,36 ± 0,66 ; p<0,01), respectively. Correlations were found between the percentage variation (Δ) of the glycemia standard deviation (ΔGSD), calculated using the CGMS, with Δ of the basal (r= 0,6; p<0,01) and total insulin (r= 0,6; p<0,01). Our study also found a correlation between the VD status after supplementation and Δ of the prandial (r= 0,5; p<0,05) and total insulin (r= 0,4; p<0,05), indicating that the better the vitamin D status, lower the doses of insulin needed by the patients. To efficiently study the GV, patients were divided in two groups: Patients in which the ΔGSD improved (group 1; N= 12 (55%)) and those in which the ΔGSD worsened (group 2; N= 10 (45%)). Group 1 when compared to group 2 showed lower needs of insulin (Δbasal insulin = -8,0 vs 6,3%; (p<0,05)) and lower frequency of hypoglycemia (12/44 (27%) vs 21/33 (64%), hypoglycemias / days evaluated ; p<0,01). Our data suggests that supplementation of VD on patients with DM1 could improve the GV associated to a lower need of insulin in more than 50% of these patients. The improvement of GV was strongly associated with reduction in frequency of hypoglycaemia. However, it was not possible to demonstrate benefits of vitamin D on glycaemic control measured by the HbA1c.Item Acesso aberto (Open Access) Polimorfismo do Gene UGT1A1 associado à toxicidade em pacientes oncológicos tratados com irinotecano (CPT-11) em Belém/PA(Universidade Federal do Pará, 2015-03-23) CARRERA, Jackeline de Sousa; MONTENEGRO, Raquel Carvalho; http://lattes.cnpq.br/0043828437326839Introduction: Studies and reviews the international scientific literature have gathered data to support the role of pharmacogenomics in clinical medicine, specifically genotype UGT1A1*28 and UGT1A1*6 as predictors of toxicity associated with therapy with CPT-11 (irinotecan), because an insert thymine-adenine in the promoter region of the UGT1A1 gene TATAbox or a single nucleotide polymorphism in exon 1 of the same gene, causing lesser extent UGT1A1 enzyme and hence lower glucuronidation of the drug. Objective: To investigate the occurrence of polymorphisms in the promoter region of the UGT1A1 gene and associate their presence with the toxicities of manifestation to CPT-11 drug in cancer patients treated at two public hospitals specialized in oncology in Belém /PA. Method: Patients in cancer treatment to CPT-11 base were accompanied by pharmacotherapeutic monitoring method as the occurrence of toxicities. Adverse reactions were assessed according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 4.0. The study also analyzed the genetic material of patients, the frequency and distribution of the polymorphism in the UGT1A1 gene by polymerase chain reaction and sequencing. As they could also be evaluated clinical and epidemiological data of the subjects. Results: A total of 31 patients were recruited, the majority (80.6%) treated with modified IFL regimen (120 mg /m² CPT-11), the most frequent gender was female (54.8%) and the primary site of the tumor , predominantly, it was the rectum (41.9%). Among the 27 patients could be genotyped none showed polymorphism in exon 1 (UGT1A1 * 6), but the following alleles were detected as the TATA promoter polymorphism in the gene, TA5/6 (3.7%), TA6/6 (44 , 4%), TA6/7 (37%) and TA7/7 (14.8%). A total of 71 toxicities were observed in 25 patients. The study population is in Hardy-Weinberg equilibrium (P = 0.135). Our study found no significant relationship between the different toxicities manifested in patients with different numbers of variant alleles, but it was observed that patients who had two alleles or a single variant allele had more medical interventions (dose reduction, delay or discontinuation of treatment) due to toxicity than patients in the wild-type allele (p = 0.016). Conclusion: The findings of this study showed a high frequency of adverse reactions to CPT-11 use in the studied patients, even low-dose protocols in relation to other studies, although they have not shown significant differences suggest the continuity of the same order to get larger sample size, considering that when the population was stratified by frequency of medical interventions motivated by toxicity, the carrier of the mutation group, heterozygous or homozygous, had higher intervention rate during treatment. Those patients can present toxicities more severe than compromise the continuity of care.Item Acesso aberto (Open Access) Vitamina D e nefropatia em pacientes com diabetes Mellitus tipo 1(Universidade Federal do Pará, 2015-10-06) LUZ, Rafael Mendonça; YAMADA, Elizabeth Sumi; http://lattes.cnpq.br/7240314827308306; FELÍCIO, João Soares; http://lattes.cnpq.br/8482132737976863Diabetes Mellitus type 1 (DM1) results from destruction of the pancreatic beta cells by an immunological process, which may progress to kidney complications. Both genetic and environmental factors are involved in the pathogenesis of type 1 diabetes, and vitamin D deficiency appears as a candidate among the risk factors for developing both diabetes and diabetic nephropathy. The objective of this study was to evaluate the existence of an association between low levels of vitamin D with the presence and degree of diabetic nephropathy in patients with type 1 diabetes. Additionally, our study aimed to establish the prevalence of vitamin D deficiency in normal individuals of our region and determine if it differs from DM1 patients. A cross-sectional study, between November 2013 and December 2014, in which levels of 25 (OH) D and albuminuria were analyzed in 37 patients with DM1, normal creatinine levels and 36 control subjects. The patients with DM1 and hypovitaminosis D had higher levels of albuminuria compared with those with normal vitamin D levels (albuminuria = log10 1.92 vs. 1.44; p <0.05). When the group of patients was separeted according to the stage of diabetic nephropathy in those with normoalbuminuria, microalbuminuria, and macroalbuminuria, we found lower levels of 25(OH)D in the latter when compared to the first two groups (26.7 ± 6.2, 24.8 and 15.9 ± 7 ± 7.6 ng / mL; p <0.05, respectively). In DM1 group, we found correlations between vitamin D levels with the levels of albuminuria and diabetic nephropathy stages (r= -0.5, p<0.01 r= -0.4; p <0.05, respectively). Additionally, the prevalence of vitamin D deficiency among control subjects was quite high (78%), and there was no difference compared to patients with DM1, whose prevalence was 73%. Patients with type 1 diabetes when compared to control group also showed no difference regarding the average levels of 25(OH)D (24.2 ± 7.4 versus 25.8 ± 11.2 ng / mL, NS). Our data suggest an association between reduced levels of vitamin D and the presence and severity of diabetic nephropathy. In addition, patients with type 1 diabetes mellitus, when compared to normal control subjects in our region did not differ in average and status of 25(OH)D levels.